MGV354

01/01/2018 - "MGV354 represents a novel class of sGC activators that can lower IOP in preclinical models of glaucoma. "
01/01/2018 - "A single topical ocular dose with MGV354 caused a significant dose-dependent reduction of 20% to 40% (versus vehicle), lasting up to 6 hours in pigmented rabbits and 24 hours postdose in a cynomolgus monkey model of glaucoma. "
01/01/2018 - "The purpose is to demonstrate that the sGC activator MGV354 lowers IOP in a monkey model of glaucoma and could be considered as a possible new clinical drug candidate. "
01/01/2021 - "MGV354 was being developed as a novel ocular therapy for lowering of intraocular pressure, a key modifiable risk factor for glaucoma. "
01/01/2018 - "A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma."

01/01/2018 - "A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma."
01/01/2021 - "However, MGV354 failed to produce similar results in patients with ocular hypertension or open-angle glaucoma. "
01/01/2018 - "To assess the clinical safety, tolerability, and efficacy of topically administered MGV354, a soluble guanylate cyclase (sGC) activator, in patients with ocular hypertension (OH) or glaucoma. "

01/01/2018 - "MGV354 produced ocular hyperemia consistent with its pharmacology."
01/01/2018 - "The most common adverse events reported after MGV354 administration were conjunctival and ocular hyperemia. "

01/01/2021 - "However, MGV354 failed to produce similar results in patients with ocular hypertension or open-angle glaucoma. "